unani formulation for menstrual irregularity associated with polycystic ovaries

Efficacy of Asgand and Khare khasak in polycystic ovarian syndrome- A Pilot Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080246

Enrollment

Registered

2025-02-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Asgand (Withania somnifera Dunal) and Khare khasak (Tribulus terrestris Linn): 7 gms twice daily from 5th day of cycle for 21 days. Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: USG findings of PCO with ovarian volume more than 10cm3 Oligomenorrhoea or amenorrhoea Clinical evidence of hyperandrogenism ( Hirsuitism or Acne)

Exclusion criteria

Exclusion criteria: 1. Patients with Hormonal treatment 2. Patients with History of DM, Hypertension, uncontrolled hypothyroidism 3. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Menstrual regularityTimepoint: Baseline and cyclical for 3 cycles	—

Secondary

Measure	Time frame
USG Changes for ovarian volume. Timepoint: baseline and after 3 months	—

Countries

India

Contacts

Public ContactDr KOUSER FATHIMA FIRDOSE

National Institute of unani medicine

kouser2fathima@gmail.com09141762284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026